Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening.

ABSTRACT:

Background

Widespread use of prostate-specific antigen (PSA) to screen for prostate cancer began in the early 1990s. Advocates for screening assert that this has caused a decrease in prostate cancer mortality. We sought to describe secular changes in prostate cancer incidence and mortality in Canada in relation to the onset of PSA screening.

Methods

Age-standardized and age-specific prostate cancer incidence (1969-2007) and mortality (1969-2009) from Public Health Agency of Canada databases were analyzed by joinpoint regression. Changes in incidence and mortality were related to introduction of PSA screening.

Results

Prior to PSA screening, prostate cancer incidence increased from 54.2 to 99.8 per 100 000 between 1969 and 1990. Thereafter, incidence increased sharply

SUBMITTER: Dickinson J 

PROVIDER: S-EPMC4866930 | biostudies-literature | 2016 Jan-Mar

REPOSITORIES: biostudies-literature